Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 2007-2013

  Silvestrini, Rosella ^a   Daidone, Maria Grazia ^a   Benini, Elvira ^a   Faranda, Alessandra ^a   Tomasic, Gorana ^a   Boracchi, Patrizia ^a   Salvadori, Bruno ^a   Veronesi, Umberto ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, CELL SURFACE; S PHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030460091     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med., 18: 1318-1327, 1993.
2. Oren, M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev., 11: 141-148, 1992.
3. Lowe, S. W., Bodis, S., McClatchey, A., Remington. L., Ruley, E., Fisher, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
4. Allred, D. C., O'Connell, P., Fuqua, S. A. W., and Osborne, C. K. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res. Treat., 32: 13-18, 1994.
5. Elledge, R. M., and Allred, D. C. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat., 32: 39-47, 1994.
6. Thor, A. D., Moore, D. H., II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
7. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst., 84: 1109-1114, 1992.
8. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
9. Bosari, S., Lee, A. K. C., Viale, G., Heatley, G. J., and Coggi, G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch. A Pathol Anat. Hist., 421: 291-295, 1992.
10. Silvestrini, R , Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V , Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965-970, 1993.
11. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., and Veronesi, U. The bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
12. Silvestrini, R., Daidone, M. G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G , Andreola, S., and Veronesi, U. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol., 13: 697-704, 1995.
13. Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., Muscolino, G., Rilke, F., Salvadori, B., Zecchini, A., and Zucali, R. Comparing radical mastectomy with quandrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N. Engl. J Med., 305: 6-11, 1981.
14. Ronchi, E., Granata, G., Brivio, M., Coradini, D., Miodini, P., and Di Fronzo, G. A double-labeling assay for simultaneous estimation and characterization of estrogen and progesterone receptors using radioiodinated estradiol and tritiated Org 2058. Tumori. 72: 251-257, 1986.
15. Silvestrini, R., Daidone, M. G., Di Fronzo, G., Morabito, A., Valagussa, P., and Bonadonna, G. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res. Treat., 7: 161-169, 1986.
16. 3H]thymidine labeling index as a prognostic indicator in node-positive breast cancer. J. Clin. Oncol., 8: 1321-1326, 1990.
17. Silvestrini, R., Daidone, M. G., Del Bino, G., Mastore, M., Di Fronzo, G., and Boracchi, P. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann. Oncol., 4: 213-219, 1993.
18. Silvestrini, R., Daidone, M. G., Mastore, M., Di Fronzo, G., Coradini, D., Boracchi, P., Squicciarini, P., Salvadori, B., and Veronesi, U. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin. Oncol., 11: 1150-1155, 1993.
19. Peduzzi, P , Concato, J., Feinstein, A. R., and Holford, T. R. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J. Clin. Epidemiol., 48: 1503-1510, 1995.
20. Berzuini, C., and Clayton, D. Bayesian analysis of survival on multiple time scales. Stat. Med., 13: 823-838, 1994.
21. Silvestrini, R., Valentinis, B., Daidone, M. G., Di Fronzo, G., Coradini, D., and Salvadori, B. Biological characterisation of primary and metachronous lesions in breast cancer patients. Eur. J. Cancer, 28: 2006-2010, 1992.
22. McGuire, W. L. Breast cancer prognostic factors: evaluation guidelines. J. Natl. Cancer Inst., 83: 154-155, 1991.
23. Clark, G. M., Wenger, C. R., Beardslee, S., Owens, M. A., Pounds, G., Oldaker, T., Vendely, P., Pandian, M. R., Harrington, D., and McGuire, W. L. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer (Phila.), 71: 2157-2162, 1993.
24. Clark, G. M., Hilsenbeck, S. G , Ravdin, P. M., De Laurentiis, M., and Osborne, C. K. Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res. Treat., 32: 105-112, 1994.
25. Battifora, H. p53 immunohistochemistry: a word of caution. Hum. Pathol., 25: 435-437, 1994.
26. Silvestrini, R., Rao, S., Benini, E., Daidone, M G., and Pilotti, S. Immunohistochemical detection of p53 in clinical breast cancers: a look at methodologic approaches. J. Natl. Cancer Inst., 87: 1020, 1995.